Combination therapy has several potential advantages, including (1) increased durability of the glycaemic effect [225,226,227], addressing therapeutic inertia, (2) simultaneous targeting of the multiple pathophysiological processes characterised by type 2 diabetes, (3) impacts on medication burden, medication-taking behaviour and treatment persistence and (4) complementary clinical benefits (e.g
PMID 6141014
In addition, chronic therapeutic doses do deplete liver GSH significantly (30%
CEOs, VPs of Manufacturing, heads of regulatory affairs, R&D directors, and commercial directors from contract manufacturers, fermentation technology suppliers, and glutathione manufacturers were examples of supply-side sources
Commercial patches are cheaper because they dont contain the actual GLP-1 medication found in prescription injections
Jakoby WB (1985)